DE3844408C2 - In 17 alpha-Stellung substituierte 17ß-Hydroxy-19-norsteroid-Derivate, deren Herstellungsverfahren, und diese enthaltende pharmazeutische Zusammensetzungen - Google Patents

In 17 alpha-Stellung substituierte 17ß-Hydroxy-19-norsteroid-Derivate, deren Herstellungsverfahren, und diese enthaltende pharmazeutische Zusammensetzungen

Info

Publication number
DE3844408C2
DE3844408C2 DE3844408A DE3844408A DE3844408C2 DE 3844408 C2 DE3844408 C2 DE 3844408C2 DE 3844408 A DE3844408 A DE 3844408A DE 3844408 A DE3844408 A DE 3844408A DE 3844408 C2 DE3844408 C2 DE 3844408C2
Authority
DE
Germany
Prior art keywords
formula
hydroxy
product
phenyl
dimethylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE3844408A
Other languages
German (de)
English (en)
Other versions
DE3844408A1 (de
Inventor
Martine Moguilewsky
Lucien Nedelec
Francois Nique
Daniel Philibert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst Roussel Vet SA France
Original Assignee
Hoechst Roussel Vet SA France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR8718376A external-priority patent/FR2625505B2/fr
Application filed by Hoechst Roussel Vet SA France filed Critical Hoechst Roussel Vet SA France
Publication of DE3844408A1 publication Critical patent/DE3844408A1/de
Application granted granted Critical
Publication of DE3844408C2 publication Critical patent/DE3844408C2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
    • C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE3844408A 1987-12-30 1988-12-30 In 17 alpha-Stellung substituierte 17ß-Hydroxy-19-norsteroid-Derivate, deren Herstellungsverfahren, und diese enthaltende pharmazeutische Zusammensetzungen Expired - Lifetime DE3844408C2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8718376A FR2625505B2 (fr) 1981-01-09 1987-12-30 Nouveaux derives steroides substitues en 11beta leur procede de preparation et leur application comme medicaments et les compositions pharmaceutiques les renfermant

Publications (2)

Publication Number Publication Date
DE3844408A1 DE3844408A1 (de) 1989-07-13
DE3844408C2 true DE3844408C2 (de) 2001-07-26

Family

ID=9358447

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3844408A Expired - Lifetime DE3844408C2 (de) 1987-12-30 1988-12-30 In 17 alpha-Stellung substituierte 17ß-Hydroxy-19-norsteroid-Derivate, deren Herstellungsverfahren, und diese enthaltende pharmazeutische Zusammensetzungen

Country Status (14)

Country Link
US (1) US5006518A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP2785023B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) AT396787B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE (1) BE1004905A4 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA1303025C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CH (1) CH676852A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE3844408C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2012197A6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (1) GB2213484B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR880100868A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IT (1) IT1235358B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (1) LU87417A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL8803196A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SE (1) SE503267C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2654337B1 (fr) * 1989-11-15 1994-08-05 Roussel Uclaf Nouvelles microspheres injectables biodegradables procede de preparation et suspensions injectables les renfermant.
DE4042004A1 (de) * 1990-12-22 1992-06-25 Schering Ag 14(beta)-h-, 14- u. 15-en-11(beta)-aryl-4-estrene
EP0496520A1 (en) * 1991-01-22 1992-07-29 Merck & Co. Inc. Novel bone acting agents
US6407082B1 (en) * 1996-09-13 2002-06-18 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a vitamin D compound
JP3862295B2 (ja) * 1993-09-30 2006-12-27 独立行政法人理化学研究所 抗肥満剤
EP0683172B1 (en) * 1994-05-19 1997-08-13 Akzo Nobel N.V. 11,21-Bisphenyl-19-norpregnane derivatives
US5780220A (en) * 1994-05-19 1998-07-14 Trustees Of The University Of Pennsylvania Methods and compositions for inhibiting HIV replication
US5639598A (en) * 1994-05-19 1997-06-17 The Trustees Of The University Of Pennsylvania Method and kit for identification of antiviral agents capable of abrogating HIV Vpr-Rip-1 binding interactions
US6765002B2 (en) 2000-03-21 2004-07-20 Gustavo Rodriguez Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium
US6028064A (en) 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
US6034074A (en) 1996-09-13 2000-03-07 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a Vitamin D compound
US6511970B1 (en) 1996-09-13 2003-01-28 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium
DE19706061A1 (de) * 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
US20010044431A1 (en) * 2000-03-21 2001-11-22 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
JP2001301596A (ja) 2000-04-19 2001-10-31 Sumitomo Denko Brake Systems Kk 車両用液圧ブレーキシステムの制御方法
US20090023914A1 (en) * 2007-05-01 2009-01-22 Alessandro Pontiroli Process for preparing drospirenone and intermediate thereof
PL2576582T3 (pl) 2010-05-26 2020-06-29 Corcept Therapeutics, Inc. Leczenie dystrofii mięśniowej
JP6821582B2 (ja) 2015-03-02 2021-01-27 コーセプト セラピューティクス， インコーポレイテッド Ａｃｔｈ分泌腫瘍を処置するための糖質コルチコイドレセプターアンタゴニストおよびソマトスタチンアナログの使用
ES2906778T3 (es) 2015-03-30 2022-04-20 Corcept Therapeutics Inc Uso de antagonistas del receptor de glucocorticoides en combinación con glucocorticoides para tratar la insuficiencia suprarrenal
CA2994422A1 (en) 2015-08-13 2017-02-16 Corcept Therapeutics, Inc. Method for differentially diagnosing acth-dependent cushing's syndrome
US11208432B2 (en) 2015-12-23 2021-12-28 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
WO2017112902A1 (en) 2015-12-23 2017-06-29 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
US11110103B2 (en) 2015-12-23 2021-09-07 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
AU2017210156B2 (en) 2016-01-19 2021-10-28 Corcept Therapeutics, Inc. Differential diagnosis of Ectopic Cushing's Syndrome
CN110099915A (zh) 2016-10-07 2019-08-06 欧瑞克制药公司 糖皮质激素受体抑制剂
RU2019129299A (ru) 2017-03-31 2021-04-30 Корсепт Терапьютикс, Инк. Модуляторы глюкокортикоидного рецептора для лечения рака шейки матки
AU2018289307B2 (en) 2017-06-20 2024-02-01 Corcept Therapeutics, Inc. Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators
JP2024500748A (ja) 2020-12-18 2024-01-10 インスティル バイオ （ユーケイ） リミテッド 腫瘍浸潤リンパ球の処理

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0057115A2 (fr) * 1981-01-09 1982-08-04 Roussel-Uclaf Nouveaux dérivés stéroides substitués en 11beta, procédé de préparation, leur application comme médicament et les compositions les renfermant

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2377418A1 (fr) * 1977-01-13 1978-08-11 Roussel Uclaf Nouveaux derives steroides 4,9-dieniques 11b-substitues, leur procede de preparation et leur application comme medicaments
FR2528434B1 (fr) * 1982-06-11 1985-07-19 Roussel Uclaf Nouveaux 19-nor steroides substitues en 11b et eventuellement en 2, leur procede de preparation et leur application comme medicament
EP0110434B1 (fr) * 1981-01-09 1986-10-29 Roussel-Uclaf Nouveaux produits intermédiaires stéroides substitués en 11-beta et procédé de préparation de ces produits
DE3461090D1 (en) * 1983-02-18 1986-12-04 Schering Ag 11-beta-aryl-estradienes, process for their preparation and pharmaceutical compositions containing them
FR2549067B1 (fr) * 1983-06-14 1985-12-27 Roussel Uclaf Derives estradieniques radioactifs marques au tritium, leur procede de preparation et leur application pour l'etude et le dosage radio-immunologique de steroides dans les fluides biologiques
ES533260A0 (es) * 1983-06-15 1985-02-01 Schering Ag Procedimiento para la preparacion de 13a-alquilgonanos
US4780461A (en) * 1983-06-15 1988-10-25 Schering Aktiengesellschaft 13α-alkyl-gonanes, their production, and pharmaceutical preparations containing same
DE3347126A1 (de) * 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen 11ss-aryl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
FR2566779B2 (fr) * 1984-06-29 1987-03-06 Roussel Uclaf Nouveaux derives steroides substitues en 11b, leur procede de preparation et leur application comme medicaments
DE3506785A1 (de) * 1985-02-22 1986-08-28 Schering AG, Berlin und Bergkamen, 1000 Berlin 11ss-n,n-dimethylaminophenyl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
DE3619413C2 (de) * 1986-06-10 2000-04-06 Schering Ag 9alpha, 10alpha-Methylen-Estrene, deren Herstellung und diese enthaltende pharmazeutische Präparate
DE3625315A1 (de) * 1986-07-25 1988-01-28 Schering Ag 11ss-(4-isopropenylphenyl)-estra-4,9-diene, deren herstellung und diese enthaltende pharmazeutische praeparate
US4774236A (en) * 1986-09-17 1988-09-27 Research Triangle Institute 17α-(substituted-methyl)-17β-hydroxy/esterified hydroxy steroids and pharmaceutical compositions containing them
IE60780B1 (en) * 1987-01-23 1994-08-10 Akzo Nv New 11-aryl steroid derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0057115A2 (fr) * 1981-01-09 1982-08-04 Roussel-Uclaf Nouveaux dérivés stéroides substitués en 11beta, procédé de préparation, leur application comme médicament et les compositions les renfermant

Also Published As

Publication number Publication date
ATA318788A (de) 1993-04-15
AT396787B (de) 1993-11-25
CA1303025C (fr) 1992-06-09
GB8830380D0 (en) 1989-03-01
JPH01213296A (ja) 1989-08-28
GB2213484A (en) 1989-08-16
GB2213484B (en) 1991-10-09
GR880100868A (el) 1994-03-31
ES2012197A6 (es) 1990-03-01
SE8804692D0 (sv) 1988-12-29
LU87417A1 (fr) 1989-06-14
IT1235358B (it) 1992-06-30
BE1004905A4 (fr) 1993-02-23
JP2785023B2 (ja) 1998-08-13
SE8804692L (sv) 1989-07-01
SE503267C2 (sv) 1996-04-29
NL8803196A (nl) 1989-07-17
DE3844408A1 (de) 1989-07-13
CH676852A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1991-03-15
US5006518A (en) 1991-04-09
IT8848730A0 (it) 1988-12-29

Similar Documents

Publication Publication Date Title
DE3844408C2 (de) In 17 alpha-Stellung substituierte 17ß-Hydroxy-19-norsteroid-Derivate, deren Herstellungsverfahren, und diese enthaltende pharmazeutische Zusammensetzungen
EP0648778B1 (de) Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
EP0192598B1 (de) 11 Beta-N,N-Dimethylaminophenyl-Estradiene, deren Herstellung und diese enthaltende pharmazeutische Präparate
DE69700470T2 (de) Neue 19-nor-pregnen-derivate
EP0299913B1 (de) 11Beta-Phenyl-4,9,15-Estratriene, deren Herstellung und diese enthaltende pharmazeutische Präparate
DE3878198T2 (de) 11-arylsteroid-derivate.
WO1988007051A1 (en) 19, 11beta-BRIDGED STEROIDS, THEIR PRODUCTION AND PHARMACEUTICAL PREPARATIONS CONTAINING SAME
EP0360369B1 (de) 11Beta-phenyl-14betaH-steroide
EP1060187A1 (de) S-substituierte 11beta-benzaldoxim-estra-4,9-dien-kohlensäurethiolester, verfahren zu deren herstellung und diese verbindungen enthaltene pharmazeutische zubereitungen
EP1525215B1 (de) Progesteronrezeptormodulatoren mit erhöhter antigonadotroper aktivität für die weibliche fertilitätskontrolle und hormonersatztherapie
DE69128820T2 (de) Neue 19-Nor Steroide, die eine Amid tragende Gruppe in der 11-Beta-Stelle haben, ihre Herstellung, ihre Verwendung als Medikamente und pharmazeutische Präparate davon
DE2107835A1 (de) Neues Pregnanderivat und Verfahren zu dessen Herstellung
DE69014012T2 (de) Organische Ester der alkoholischen Derivate der 19-nor-Steroide und die Salze davon, Verfahren zu deren Herstellung und Zwischenprodukte davon, ihre Verwendung als Arzneimittel und pharmazeutische Präparate davon.
DE3617883A1 (de) In 11(beta)-stellung substituierte steroide und verfahren zu deren herstellung
DE1468902B1 (de) 25-Aza-19-nor-1,3,5(10)-cholestatriene und deren therapeutisch vertraegliche Saeureadditionssalze sowie ein Verfahren zur Herstellung dieser Verbindungen
EP0320438B1 (de) 17-Halogenmethylen-estratriene
DE2748250C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE60026608T2 (de) 3-methylen steroid derivate zur behandlung von autoimmunerkrankungen
DE602005003564T2 (de) Progesteronrezeptormodulatoren
FR2625505A2 (fr) Nouveaux derives steroides substitues en 11beta leur procede de preparation et leur application comme medicaments et les compositions pharmaceutiques les renfermant
DE3644358A1 (de) 10(beta)-alkynyl-4,9(11)-oestradien-derivate, verfahren zu deren herstellung und arzneimittel, welche diese enthalten
DE1793738C3 (de) 3-0A-11 beta-OB-17alpha-R-17beta-OH-östra-1,3,5 (10)-trlene und diese enthaltende Arzneimittel
DE1210818B (de) Verfahren zur Herstellung von 1, 1-AEthylen-17alpha-alkyl-delta 2-5alpha-androsten-17beta-olen und deren 17-Estern
DE1668661B2 (de) 6-cyansteroide und verfahren zu deren herstellung
DE3644301A1 (de) 10ss-halo-alkynyloestren-derivate, verfahren zu deren herstellung und arzneimittel, welche diese enthalten

Legal Events

Date Code Title Description
8110 Request for examination paragraph 44
8127 New person/name/address of the applicant

Owner name: HOECHST ROUSSEL VET S.A., ROMAINVILLE, FR

D2 Grant after examination
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: PFENNING MEINIG & PARTNER GBR, 80339 MUENCHEN